[Is procalcitonin measurement useful in managing respiratory tract infections?]

Area of Science:

• Clinical Microbiology and Infectious Diseases
• Pulmonology
• Health Services Research

Background:

• Rising antimicrobial resistance necessitates improved antibiotic stewardship.
• Procalcitonin (PCT) testing is proposed to guide antibiotic use in respiratory tract infections (RTIs).
• Current guidelines often discourage antibiotic use for conditions like acute bronchitis and COPD exacerbations.

Purpose of the Study:

• To evaluate the effectiveness of procalcitonin guidance in reducing antibiotic usage and duration in adult RTIs.
• To explore the potential of host gene expression assays for diagnosing the etiology of community-acquired pneumonia (CAP).
• To identify barriers to guideline adherence in antibiotic prescribing for RTIs.

Main Methods:

• Review of studies on procalcitonin-guided antibiotic initiation and discontinuation in adult RTIs.
• Analysis of procalcitonin's impact on treatment duration for community-acquired pneumonia.
• Discussion of host gene expression patterns as a diagnostic tool for respiratory illness etiology.

Main Results:

• Procalcitonin guidance can reduce antibiotic use, primarily in acute bronchitis and COPD exacerbations where antibiotics are generally not recommended.
• Sequential PCT measurements can shorten CAP treatment duration, but often to durations already recommended by current guidelines.
• Host gene expression assays show promise for diagnosing the cause of acute respiratory illness.

Conclusions:

• While procalcitonin can reduce antibiotic consumption, its main impact is in conditions where antibiotics are already discouraged.
• Investigating physician adherence to existing antibiotic guidelines may be more impactful than introducing new diagnostic tests.
• Host gene expression profiling offers a potential future strategy for guiding antibiotic therapy by determining the etiology of CAP.